IBCSG 49-14 PENELOPE

Phase III study evaluating palbociclib (PD-0332991), a CyclinDependent Kinase (CDK) 4/6 Inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy.

Study Chair
Dr. Marco Colleoni, EIO Milano, Italy

Statistician
Valentina Nekljudova, GBG Forschungs GmbH, Neu-Isenburg, Germany

Director of the Data Management Center
Holly Shaw

Monitoring
ETOP IBCSG Partners Foundation
Coordinating Center, Bern, Switzerland
Phone: +41 31 511 94 00
Fax: +41 31 511 94 01
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

IBCSG Data Management Center/Frontier Science Foundation
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Date of Activation

Targeted Accrual
800

ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: contact@etop.ibcsg.org